Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo

Folia Parasitologica

Volumn 52, Issue 1-2, 2005, Pages 173-181

  Didier, Elizabeth S ^a   Bowers, Lisa ^a   Stovall, Mary E ^a   Kuebler, Dorothy ^a   Mittleider, Derek ^b   Brindley, Paul J ^b   Didier, Peter J ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Emerging infection; Encephalitozoon intestinalis; Fluoroquinolone; Microsporidia; Opportunistic infection; Vittaforma corneae

Indexed keywords

ANIMALIA; ENCEPHALITOZOON INTESTINALIS; MAMMALIA; MICROSPORIDIA; MUS MUSCULUS; NOSEMA; VITTAFORMA CORNEAE;

EID: 20444506110     PISSN: 00155683     EISSN: None     Source Type: Journal    
DOI: 10.14411/fp.2005.022     Document Type: Conference Paper

References (53)

1. ANDERSSON M.I., MacGOWAN A.P. 2003: Development of the quinolones. J. Antimicrob. Chemother. 51 (Suppl. 1): 1-11.
2. BAKER M.D., VOSSBRINCK C.R., DIDIER E.S., MADDOX J.V., SHADDUCK J.A. 1995: Small subunit ribosomal DNA phylogeny of various microsporidia with emphasis on AIDS related forms. J. Eukaryot. Microbiol. 42: 564-570.
3. BALL P. 2000: Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 46 (Suppl. T1): 17-24.
4. BIANCIARDI P., FASANELL A., FOGLIA A., MANZILLO V., TROTTA T., PAGANO A., SORINO S., GRADONI L., OLIVA G. 2004: The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol. Res. 93: 486-492.
5. BLANSHARD C., ELLIS D.S., TOVEY D.G., DOWELL S., GAZZARD B.G. 1992: Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 6: 311-313.
6. BRYAN R.T., SCHWARTZ D.A. 1999: Epidemiology of microsporidiosis. In: M. Wittner and L.M. Weiss (Eds.), The Microsporidia and Microsporidiosis. ASM Press, Washington, D.C., pp. 502-516.
7. CALI A., KOTLER D.P., ORENSTEIN J.M. 1993: Septata intestinalis n. g., n. sp., an intestinal microsporidian associated with chronic diarrhea and dissemination in AIDS patients. J. Eukaryot. Microbiol. 40: 101-112.
8. CAVALIER-SMITH T. 1998: A revised six-kingdom system of life. Biol. Rev. Camb. Philos. Soc. 73: 203-266.
9. CHAMPOUX J.J. 2001: DNA topoisomerases: structure, function, and mechanism. Ann. Rev. Biochem. 70: 369-413.
10. CHAN C.M., THENG J.T., LI L., TAN D.T. 2003: Microsporidial keratoconjunctivitis in healthy individuals: a case series. Ophthalmology 110: 1420-1425.
11. CHAVALITSHEWINKOON-PETMITR P., WORASING R., WILAIRAT P. 2001: Partial purification of mitochondrial DNA topoisomerase II from Plasmodium falciparum and its sensitivity to inhibitors. S.E. Asian J. Trop. Med. Public Health 32: 733-738.
12. CONTEAS C.N., BERLIN O.G., ASH L.R., PRUTHI J.S. 2000: Therapy for human gastrointestinal microsporidiosis. Am. J. Trop. Med. Hyg. 63: 121-127.
13. DESPORTES-LIVAGE I. 2000: Biology of microsporidia. Contrib. Microbiol. 6: 140-165.
14. DIDIER E.S. 1997: Effects of albendazole, fumagillin, and TNP-470 on microsporidia replication in vitro. Antimicrob. Agents Chemother. 41: 1541-1546.
15. DIDIER E.S. 2005: Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta Trop. 94: 61-76.
16. DIDIER E.S., ROGERS L.B., ORENSTEIN J.M., BAKER M.D., VOSSBRINCK C.R., VAN GOOL T., HARTSKEERL R., SOAVE R., BEAUDET L.M. 1996: Characterization of Encephalitozoon (Septata) intestinalis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J. Eukaryot. Microbiol. 43: 34-43.
17. DIDIER E.S., VARNER P.W., DIDIER P.J., ALDRAS A.M., MILLICHAMP N.J., MURPHEY-CORB M., BOHM R.P., SHADDUCK J.A. 1994: Experimental microsporidiosis in immunocompetent and immunodeficient mice and monkeys. Folia Parasitol. 41: 1-11.
18. DIVO A.A., SARTORELLI A.C., PATTON C.L., BIA F.J. 1988: Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 32: 1182-1186.
19. DRLICA K., ZHAO X. 1997: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61: 377-392.
20. EMMERSON A.M., JONES A.M. 2003: The quinolones: decades of development and use. J. Antimicrob. Chemother. 51 (Suppl. 1): 13-20.
21. FICHERA M.E., ROOS D.S. 1997: A plastid organelle as a drug target in apicomplexan parasites. Nature 390: 407-409.
22. FRIEDBERG D.N., RITTERBAND D.C. 1999: Ocular microsporidiosis. In: M. Wittner and L.M. Weiss (Eds.), The Microsporidia and Microsporidiosis. ASM Press, Washington, D.C., pp. 293-314.
23. GOZALBES R., BRUN-PASCAUD M., GARCIA-DOMENECH R., GALVEZ J., GIRARD P.M., DOUCET J.P., DEROUIN F. 2000: Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques. Antimicrob. Agents Chemother. 44: 2771-2776.
24. HAMZAH J., SKINNER-ADAMS T., DAVIS T.M. 2000: In vitro antimalarial activity of trovafloxacin, a fourth-generation fluoroquinolone. Acta Trop. 74: 39-42.
25. HAWKEY P.M. 2003: Mechanisms of quinolone action and microbial response. J. Antimicrob. Chemother. 51 (Suppl. 1): 29-35.
26. HINKLE G., MORRISON H.G., SOGIN M.L. 1997: Genes coding for reverse transcriptase, DNA-directed RNA polymerase, and chitin synthase from the microsporidian Spraguea lophii. Biol. Bull. 193: 250-251. (http://jbpc.mbl. edu/Spraguea-html/)
27. HOOPER D.C. 2000: Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31 (Suppl. 2): S24-S28.
28. HOOPER D.C. 2001: Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32 (Suppl. 1): 9-15.
29. INCE D., HOOPER D.C. 2003: Quinolone resistance due to reduced target enzyme expression. J. Bacteriol. 185: 6883-6892.
30. KATINKA M.D., DUPRAT S., CORNILLOT E., MÉTÉNIER G., THOARAT F., PRENSIER G., BARE V., PEYRETAILLADE E., BROTTIER P., WINCKER P., DELBAC F., El ALAOUI H., PEYRET P., SAURIN W., GOUY M., WEISSENBACH J., VIVARÈS C.P. 2001: Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi. Nature 414: 450-453.
31. KATZNELSON H., JAMIESON C.A. 1952: Control of nosema disease of honeybees with fumagillin. Science 115: 70-71.
32. KEELING P.J., FAST N.M. 2002: Microsporidia: biology and evolution of highly reduced intracellular parasites. Ann. Rev. Microbiol. 56: 93-116.
33. KHAN A.A., SLIFER T., ARAUJO F.G., POLZER R.J., REMINGTON J.S. 1997: Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Antimicrob. Agents Chemother. 41: 893-897.
34. KHAN A.A., SLIFER T., ARAUJO F.G., REMINGTON J.S. 1996: Trovafloxacin is active against Toxoplasma gondii. Antimicrob. Agents Chemother. 40: 1855-1859.
35. KOTLER D.P., ORENSTEIN J.M. 1998: Clinical syndromes associated with microsporidiosis. Adv. Parasitol. 40: 321-349.
36. KOTLER D.P., ORENSTEIN J.M. 1999: Clinical syndromes associated with microsporidiosis. In: M. Wittner and L.M. Weiss (Eds.), The Microsporidia and Microsporidiosis. ASM Press, Washington, D.C., pp. 258-292.
37. MITTLEIDER D., GREEN L.C., MANN V.H., MICHAEL S.F., DIDIER E.S., BRINDLEY P.J. 2002: Survey of genome sequences from the opportunistic microsporidian pathogen, Vittaforma corneae. J. Eukaryot. Microbiol. 49: 393-401.
38. MOLINA J.M., TOURNEUR M., SARFATI C., CHEVRET S., DE GOUVELLO A., GOBERT J.G., BALKAN S., DEROUIN F. and Agence Nationale de Recherches sur le SIDA 090 Study Group. 2002: Fumagillin treatment of intestinal microsporidiosis. N. Engl. J. Med. 346: 1963-1969.
39. NENORTAS E.C., BODLEY A.L., SHAPIRO T.A. 1998: DNA topoisomerases: a new twist for antiparasitic chemotherapy? Biochim. Biophys. Acta 1400: 349-354.
40. NENORTAS E., BURRI C., SHAPIRO T.A. 1999: Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Chemother. 43: 2066-2068.
41. NENORTAS E., KULIKOWICZ T., BURRI C., SHAPIRO T.A. 2003: Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob. Agents Chemother. 47: 3015-3017.
42. RUIZ J. 2003: Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51: 1109-1117.
43. SARMA P.S. 1989: Norfloxacin: a new drug in the treatment of falciparum malaria. Ann. Intern. Med. 111: 336-337.
44. SHADDUCK J.A. 1980: Effect of fumagillin on in vitro multiplication of Encephalitozoon cuniculi. J. Protozool. 27: 202-208.
45. SHADDUCK J.A., MECCOLI R.A., DAVIS R., FONT R.L. 1990: Isolation of a microsporidian from a human patient. J. Infect. Dis. 162: 773-776.
46. SOUSA M.C., POIARES-da-SILVA J. 2001: The cytotoxic effects of ciprofloxacin in Giardia lamblia trophozoites. Toxicol. In Vitro 15: 297-301.
47. TRIPATHI K.D., SHARMA A.K., VALECHA N., BISWAS S. 1993: In vitro activity of fluoroquinolones against chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Indian J. Malariol. 30: 67-73.
48. VIVARÈS C.P., GOUY M., THOARAT F., MÉTÉNIER G. 2002: Functional and evolutionary analysis of a eukaryotic parasitic genome. Curr. Opin. Microbiol. 5: 499-505.
49. VOSSBRINCK C.R., ANDREADIS T.G., WEISS L.M. 2004: Phylogenetics: taxonomy and the microsporidia as derived fungi. In: D.S. Lindsay and L.M. Weiss (Eds.), Opportunistic Infections: Toxoplasma, Sarcocystis, and Microsporidia. Kluwer Academic Publishers, Boston, pp. 189-213.
50. VOSSBRINCK C.R., MADDOX J.V., FRIEDMAN S.S., DEBRUNNER-VOSSBRINCK B.A., WOESE C.R. 1987: Ribosomal RNA sequence suggests microsporidia are extremely ancient eukaryotes. Nature 326: 411-414.
51. WATT G., SHANKS G.D., EDSTEIN M.D., PAVANAND K., WEBSTER H.K., WECHGRITAYA S. 1991: Ciprofloxacin treatment of drug-resistant falciparum malaria. J. Infect. Dis. 164: 602-604.
52. WEBER R., DEPLAZES P., SCHWARTZ D. 2000: Diagnosis and clinical aspects of human microsporidiosis. Contrib. Microbiol. 6: 166-192.
53. WEISS L.M., EDLIND T.D., VOSSBRINCK C.R., HASHIMOTO T. 1999: Microsporidian molecular phylogeny: the fungal connection. J. Eukaryot. Microbiol. 46: 17S-18S.